Načítá se...

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and carries a dismal prognosis. The EGFR gene is among the most commonly deranged genes in GBM and thus an important therapeutic target. We report the case of a young female with heavily pretreated EGFR-mutated GBM, for wh...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:CNS Oncol
Hlavní autoři: Makhlin, Igor, Salinas, Ryan D, Zhang, Daniel, Jacob, Fadi, Ming, Gou-li, Song, Hongjun, Saxena, Deeksha, Dorsey, Jay F, Nasrallah, MacLean P, Morrissette, Jennifer JD, Binder, Zev A, O'Rourke, Donald M, Desai, Arati S, Brem, Steven, Bagley, Stephen J
Médium: Artigo
Jazyk:Inglês
Vydáno: Future Medicine Ltd 2019
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6880297/
https://ncbi.nlm.nih.gov/pubmed/31769726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns-2019-0014
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!